2.85
price down icon3.06%   -0.09
after-market Handel nachbörslich: 2.85
loading
Schlusskurs vom Vortag:
$2.94
Offen:
$2.99
24-Stunden-Volumen:
795.31K
Relative Volume:
1.13
Marktkapitalisierung:
$198.98M
Einnahmen:
$63.63M
Nettoeinkommen (Verlust:
$10.62M
KGV:
57.00
EPS:
0.05
Netto-Cashflow:
$-8.64M
1W Leistung:
+9.20%
1M Leistung:
+12.65%
6M Leistung:
+163.89%
1J Leistung:
+141.53%
1-Tages-Spanne:
Value
$2.84
$3.04
1-Wochen-Bereich:
Value
$2.50
$3.04
52-Wochen-Spanne:
Value
$0.8214
$3.04

Protalix BioTherapeutics Inc. Stock (PLX) Company Profile

Name
Firmenname
Protalix BioTherapeutics Inc.
Name
Telefon
972 4 988 9488
Name
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Name
Mitarbeiter
190
Name
Twitter
@Protalix_Bio
Name
Nächster Verdiensttermin
2025-03-17
Name
Neueste SEC-Einreichungen
Name
PLX's Discussions on Twitter

Vergleichen Sie PLX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PLX
Protalix BioTherapeutics Inc.
2.85 198.98M 63.63M 10.62M -8.64M 0.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-06-08 Bestätigt H.C. Wainwright Buy
2017-04-17 Bestätigt Rodman & Renshaw Buy
2016-04-04 Eingeleitet Rodman & Renshaw Buy
2015-04-23 Hochstufung Jefferies Hold → Buy
2014-11-12 Bestätigt R. F. Lafferty Buy
2014-01-24 Eingeleitet R. F. Lafferty Buy
2012-05-02 Herabstufung Canaccord Genuity Buy → Hold
2012-05-02 Bestätigt Oppenheimer Outperform
2012-04-30 Herabstufung Auriga Buy → Hold
2011-10-13 Eingeleitet Morgan Joseph Hold
2011-03-17 Herabstufung WBB Securities Strong Buy → Buy
2010-11-09 Bestätigt Oppenheimer Outperform
2010-10-14 Bestätigt UBS Buy
2009-12-02 Bestätigt Hapoalim Outperform
2009-09-22 Eingeleitet Canaccord Adams Buy
2009-09-02 Eingeleitet Hapoalim Outperform
2008-12-01 Bestätigt Oppenheimer Outperform
2008-03-11 Eingeleitet UBS Buy
2007-11-20 Eingeleitet CIBC Wrld Mkts Sector Outperform
Alle ansehen

Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten

pulisher
Apr 24, 2025

PLX’s earnings estimates: Are they on track to meet expectations? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Protalix BioTherapeutics Inc Inc. (PLX) Price Performance: A Technical Analysis Perspective - investchronicle.com

Apr 24, 2025
pulisher
Apr 24, 2025

Protalix CFO Eyal Rubin to resign in six months By Investing.com - Investing.com Nigeria

Apr 24, 2025
pulisher
Apr 23, 2025

Protalix BioTherapeutics' CFO Rubin to Leave - MarketWatch

Apr 23, 2025
pulisher
Apr 23, 2025

Protalix stock soars to 52-week high, hits $2.76 By Investing.com - Investing.com South Africa

Apr 23, 2025
pulisher
Apr 23, 2025

Eyal Rubin Resigns As CFO Of Protalix BiotherapeuticsSEC Filing - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

Protalix CFO Eyal Rubin to resign in six months - Investing.com

Apr 23, 2025
pulisher
Apr 23, 2025

The growth track for Protalix BioTherapeutics Inc (PLX) has changed recently - Sete News

Apr 23, 2025
pulisher
Apr 10, 2025

Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline - Seeking Alpha

Apr 10, 2025
pulisher
Apr 10, 2025

Fabry Disease Treatment Market Opportunity and Forecast Report 2025-2034 Featuring Amicus Therapeutics, Avrobio, Freeline, Idorsia, ISU Abxis, JCR, Novartis, Pfizer, Protalix, Sanofi, Takeda, Viatris - Yahoo Finance

Apr 10, 2025
pulisher
Apr 06, 2025

Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020 - BioSpace

Apr 06, 2025
pulisher
Apr 04, 2025

Fabry Disease Treatment Market Deep Research 2025-2032 | - openPR.com

Apr 04, 2025
pulisher
Apr 01, 2025

Virtu Financial LLC Has $64,000 Stock Holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World

Apr 01, 2025
pulisher
Mar 26, 2025

[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.

Mar 26, 2025
pulisher
Mar 26, 2025

Protalix Biotherapeutics is developing innovative treatments for rare diseases with its proprietary ProCellEx plant cell expression system - Proactive financial news

Mar 26, 2025
pulisher
Mar 26, 2025

Protalix BioTherapeutics And 2 Other Promising Penny Stocks - simplywall.st

Mar 26, 2025
pulisher
Mar 24, 2025

Protalix to present at iAccess Alpha Virtual Investment Conference 2025 - Proactive financial news

Mar 24, 2025
pulisher
Mar 24, 2025

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 - Financial Times

Mar 24, 2025
pulisher
Mar 22, 2025

Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now? - Insider Monkey

Mar 22, 2025
pulisher
Mar 21, 2025

Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive Investors

Mar 21, 2025
pulisher
Mar 21, 2025

Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipelineICYMI - Proactive financial news

Mar 21, 2025
pulisher
Mar 21, 2025

FY2025 Earnings Estimate for PLX Issued By Zacks Small Cap - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge - markets.businessinsider.com

Mar 20, 2025
pulisher
Mar 18, 2025

Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors

Mar 18, 2025
pulisher
Mar 18, 2025

Protalix Biotherapeutics gains momentum: analysts see long-term upside - Proactive Investors USA

Mar 18, 2025
pulisher
Mar 18, 2025

Protalix BioTherapeutics pipeline eyes gout treatment as financial strength fuels future growth - Proactive financial news

Mar 18, 2025
pulisher
Mar 18, 2025

Protalix BioTherapeutics : Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate - Proactive Investors UK

Mar 18, 2025
pulisher
Mar 18, 2025

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

PLX: 2024 Results - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... - Yahoo

Mar 18, 2025
pulisher
Mar 18, 2025

Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... By GuruFocus - Investing.com Canada

Mar 18, 2025
pulisher
Mar 18, 2025

Protalix BioTherapeutics Reports Record Revenue and Clinical Progress - TipRanks

Mar 18, 2025
pulisher
Mar 17, 2025

Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Protalix plans Phase 2 for PRX-115 in H2 2025, projects higher royalty revenues by 2030 - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Protalix BioTherapeutics Inc. (DE) (PLX) reports earnings - Quartz

Mar 17, 2025
pulisher
Mar 17, 2025

Protalix Q4 Earnings Fall, Stock Up In Pre-market - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results - GuruFocus.com

Mar 17, 2025
pulisher
Mar 14, 2025

StockNews.com Upgrades Protalix BioTherapeutics (NYSE:PLX) to “Strong-Buy” - Defense World

Mar 14, 2025
pulisher
Mar 10, 2025

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference - Kilgore News Herald

Mar 10, 2025
pulisher
Mar 10, 2025

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 - Quantisnow

Mar 10, 2025
pulisher
Mar 10, 2025

Protalix BioTherapeutics to Report FY2024 Earnings on March 17 - Stock Titan

Mar 10, 2025
pulisher
Mar 09, 2025

Protalix BioTherapeutics (NYSE:PLX) and INmune Bio (NASDAQ:INMB) Head-To-Head Review - The AM Reporter

Mar 09, 2025
pulisher
Mar 09, 2025

Protalix Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 06, 2025

Y Intercept Hong Kong Ltd Acquires Shares of 18,818 Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World

Mar 06, 2025
pulisher
Feb 24, 2025

Protalix Biotherapeutics poised for profitability as rare disease drug gains momentum - Proactive financial news

Feb 24, 2025

Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):